Transparency and Trust in Gene Therapy

This chapter explores the controversy surrounding a patient advocacy group's video that criticized Sarepta's gene therapy, elevitis. It highlights the ethical implications of corporate influence on patient advocacy and the hesitations faced by patients regarding new treatments amidst incomplete data. The discussion raises important questions on the dynamics between biotechnology companies and the advocacy community, especially concerning transparency and accountability.